Granzyme B in Autoimmune Skin Disease

Area of Science:

• Dermatology
• Immunology
• Molecular Biology

Background:

• Autoimmune skin diseases cause significant morbidity, with limited treatment options beyond corticosteroids.
• Current treatments have adverse effects, highlighting the need for targeted therapies.
• Granzyme B (GzmB), a serine protease, is implicated in skin barrier dysfunction and inflammation.

Purpose of the Study:

• To review the role of Granzyme B (GzmB) in autoimmune skin diseases.
• To explore GzmB as a potential therapeutic target for conditions like pemphigoid disease, vitiligo, and alopecia areata.

Main Methods:

• Literature review of studies investigating Granzyme B in various autoimmune skin conditions.
• Analysis of GzmB's functions including cytotoxicity, extracellular matrix degradation, and role in autoimmune pathogenesis.

Main Results:

• Granzyme B is significantly elevated in conditions such as alopecia areata, interface dermatitis, pemphigoid disease, psoriasis, systemic sclerosis, and vitiligo.
• GzmB is causally involved in pemphigoid disease development and has diagnostic/prognostic value in cutaneous lupus erythematosus, vitiligo, and alopecia areata.
• GzmB contributes to impaired barrier function, inflammation, and blistering in autoimmune skin diseases.

Conclusions:

• Granzyme B is a key molecular driver in several autoimmune skin diseases.
• Targeting Granzyme B presents a novel therapeutic avenue for autoimmune skin conditions.
• Further research into GzmB inhibition could lead to improved treatment outcomes.